OncoMatch/Clinical Trials/NCT06856447
The Role of Coenzyme Q10 in the Prophylaxis of Oxaliplatin Induced Peripheral Neuropathy in Patients With Colorectal Cancer
Is NCT06856447 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments for colorectal cancer.
Treatment: Coenzyme Q10 · Oxaliplatin · 5-Fluorouracil (5-FU) · 5-HT3 Antagonist · Pantoprazole — This study aims to evaluate the possible beneficial role of coenzyme Q10 against oxaliplatin-induced peripheral neuropathy in patients with colorectal cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Disease stage
Required: Stage III
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: neurotoxic agent (cisplatin, vincristine, paclitaxel, docetaxol, foscarnet, INH)
Patients with prior exposure to neurotoxic agents (Cisplatin, vincristine, paclitaxel, docetaxol, foscarnet, INH, etc..) in the last 6 months.
Lab requirements
Blood counts
absolute neutrophilic count ≥ 1.5 × 10^9 /L, platelet count ≥ 100 × 10^9 /L and hemoglobin level ≥ 10 g/dl
Kidney function
serum creatinine < 1.5 mg/dl
Liver function
serum bilirubin < 1.2 mg/dl
Adequate baseline hematologic values (absolute neutrophilic count ≥ 1.5 × 10^9 /L, platelet count ≥ 100 × 10^9 /L and hemoglobin level ≥ 10 g/dl). Patients with adequate renal function (serum creatinine < 1.5 mg/dl). Patients with adequate liver function (serum bilirubin < 1.2 mg/dl).
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify